Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.66 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | MITF | O75030 | 1/20 | 0.51 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | FLT3 | P36888 | 2/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL839341 | 0.80 | ALDH1A1 (0.51) | ALDH1A1MAPTSMN1; SMN2TP53NPC1 | |
| SCHEMBL839165 | 0.78 | ALDH1A1 (0.69) | ALDH1A1MAPTMAPK1SMN1; SMN2TP53 | |
| SCHEMBL24846388 | 0.74 | ENPP1 (0.70) | ALDH1A1SMN1; SMN2TP53NPC1RAB9A | |
| SCHEMBL24847136 | 0.73 | ALDH1A1 (0.73) | ALDH1A1MAPTMAPK1SMN1; SMN2L3MBTL1 | |
| SCHEMBL14027517 | 0.69 | POLB (0.65) | ALDH1A1MAPTSMN1; SMN2TP53NPC1 | |
| SCHEMBL18689394 | 0.68 | ALDH1A1 (0.58) | ALDH1A1MAPTSMN1; SMN2TP53NPC1 | |
| SCHEMBL7930206 | 0.67 | RAB9A (0.65) | ALDH1A1MAPTSMN1; SMN2TP53NPC1 | |
| SCHEMBL7735911 | 0.66 | MITF (0.63) | ALDH1A1MAPTSMN1; SMN2TP53NPC1 | |
| SCHEMBL517540 | 0.66 | MITF (0.63) | ALDH1A1SMN1; SMN2TP53NPC1RAB9A | |
| SCHEMBL3824110 | 0.66 | MITF (0.63) | ALDH1A1MAPTSMN1; SMN2TP53NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143263-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2012-03-27 | — | — | US | disclosed |
| US-8071585-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2011-12-06 | — | — | US | disclosed |
| US-8071608-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2011-12-06 | — | — | US | disclosed |
| EP-2324028-A2 | THERAPEUTIC AGENTS 414 | AstraZeneca AB (SE) | 2011-05-25 | — | — | EP | disclosed |
| WO-2010116176-A1 | PYRAZOLO [4, 5-E] PYRIMIDINE DERIVATIVE AND ITS USE TO TREAT DIABETES AND OBESITY | ASTRAZENECA AB (SE) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010116177-A1 | A PYRAZOLO [4,5-E] PYRIMIDINE DERIVATIVE AND ITS USE TO TREAT DIABETES AND OBESITY | ASTRAZENECA AB (SE) | 2010-10-14 | — | — | WO | disclosed |
| US-20100261704-A1 | THERAPEUTIC AGENTS 928 | ASTRAZENECA AB (SE) | 2010-10-14 | — | — | US | disclosed |
| US-20100261733-A1 | THERAPEUTIC AGENTS 927 | ASTRAZENECA AB (SE) | 2010-10-14 | — | — | US | disclosed |
| US-20100093757-A1 | THERAPEUTIC AGENTS 414 | ASTRAZENECA AB (SE) | 2010-04-15 | — | — | US | disclosed |
| WO-2010015849-A2 | THERAPEUTIC AGENTS 414 | ASTRAZENECA AB (SE) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261704-A1 | THERAPEUTIC AGENTS 928 | GCK, GCKR, GALK1 | ALDH1A1 2144/4885MAPT 4030/4885MAPK1 773/4885 |
| US-20100093757-A1 | THERAPEUTIC AGENTS 414 | GCK, GCKR, GPR119 | ALDH1A1 1918/4885MAPT 3944/4885MAPK1 569/4885 |
| US-20100261733-A1 | THERAPEUTIC AGENTS 927 | GCK, GCKR, GALK1 | ALDH1A1 2427/4885MAPT 3932/4885MAPK1 390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.